Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
Status:
Completed
Trial end date:
2020-09-21
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of ipilimumab and
ABI-007 (abraxane) can help to control metastatic melanoma. The safety of this drug
combination will also be studied.
Ipilimumab is designed to increase the immune system's ability to fight cancer.
Abraxane is designed to stop cancer cells from making new DNA (the genetic material of
cells). This may stop the cancer cells from dividing into new cells.